Business Wire

Trolley Introduces First DAC7 Compliant Payout Tool, End-to-End Solution for Reporting Online Marketplace Earnings to EU Tax Authorities

20.6.2023 16:24:00 EEST | Business Wire | Press release

Share

Trolley, the payouts platform for the internet economy, is pleased to announce a major expansion of its Tax product, now allowing online marketplaces across the globe to pay out and report on payments to European sellers in full compliance with the EU’s stringent DAC7 reporting obligations.

For online marketplaces with hundreds or thousands of non-employee sellers, complying with global tax regulations can be challenging at scale, difficult to do manually, and may slow down business growth. With this new multi-jurisdiction solution for the EU’s DAC7 regulations, Trolley is automating the whole process, offering an end-to-end DAC7 Compliance product that works regardless of which of the 27 EU member states is being used for reporting purposes.

Key features of the new product include:

  • A self-serve, white-label onboarding experience that collects all information required by the DAC7 rules & cuts down on manual processes;
  • Income type payment tagging supporting for all four “activities” reportable under DAC7: provision of services, selling of goods, sales of means of transportation, and rental of immovable property;
  • Automatic tax and payment record management throughout the year; and,
  • Automated production of authority-ready XML files at the end of the year for the tax authority in the reporting country of the merchant’s choice.

Together with Trolley’s current US IRS Compliance product, customers who leverage the DAC7 product will have peace of mind knowing that they are compliant in even more countries — all from one platform, and without needing to make use of a third-party provider.

A Challenging New Set of Rules for the Gig Economy

Navigating the scope of various tax rules can be a complex process for businesses that operate online, but it’s crucial for digital platforms to understand and keep up with their tax obligations, especially with the new DAC7 regulations reportable for the first time on Jan 31, 2024.

“Understanding tax laws can be challenging to begin with, and DAC7 is no exception. While regulations like these help governments fight against tax fraud and evasion, they also help sellers to better comply with their own tax obligations,” says Tax Subject Matter Expert Jessalyn Dean, CPA. “Online retailers need to keep these complex rules in mind at each stage of the seller journey to help balance the needs of the government and the needs of the seller. It’s important for marketplaces to think about DAC7 not just as a regulatory obligation, but as a potential benefit for your sellers.”

How Trolley's DAC7 Product Helps Marketplaces with Global Ambitions

For online marketplaces based in the EU or paying sellers in the EU, DAC7 reporting requirements will be compulsory starting in 2024, which means that companies need to start collecting data ASAP.

“We’ve had conversations with accounting, tax and operations teams about how they’re going to solve the challenges of DAC7,” says Barnett Klane, VP Product at Trolley. “It was a no-brainer for us; we needed to help platforms working with sellers in the EU address the challenges of scaling their complex global payouts and generate compliant end-of-year tax reporting. This new turnkey solution simplifies and automates the entire DAC7 workflow.”

The EU is one of the first groups of countries to adopt tax rules specifically targeted at online marketplaces, but others, like the UK and Canada, will be following suit. The Trolley team is already anticipating the future needs of even more jurisdictions, and ready to adapt their Tax product to meet those requirements.

For more information, visit trolley.com/tax/dac7-compliance/

About Trolley

Trolley is building the payouts platform for the internet economy. With a fully customizable payout management platform and robust IRS (1099/1042-S) & DAC7 compliant tax reporting suite, Trolley allows companies to make and manage payments to recipients in 210+ countries and territories. Trolley is quickly becoming the payouts platform of choice for businesses that need to pay creators, musicians, artists, freelancers, vendors, on-demand workers, or any other supplier. More information is available at trolley.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Myles Carter
Director of Content Marketing
P: 514-554-2377
E: myles.carter@trolley.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye